The mitochondrial calcium uniporter (MCU) transports free ionic Ca 2+ into the mitochondrial matrix. We assessed MCU expression in clinical breast cancer samples using microarray analysis and the consequences of MCU silencing in a breast cancer cell line. Our results indicate that estrogen receptor negative and basal-like breast cancers are charact erized by elevated levels of MCU. Silencing of MCU expression in the basal-like MDA-MB-231 breast cancer cell line produced no change in prolifera tion or cell viability. However, distinct consequences of MCU silencing were seen on cell death pathways. Caspase-dependent cell death initi ated by the Bcl-2 inhibitor ABT-263 was not altered by MCU silencin g; whereas caspaseindependent cell death induced by the calcium ionophore ionomycin was potentiated by MCU silencin g. Measurement of cytosolic Ca 2+ levels showed that the promotion of ionomycin-induced cell death by MCU silencing occurs independently of changes in bulk cytosolic Ca 2+ leve ls. This study demonstrates that MCU overexpre ssion is a feature of some breast cancers and that MCU overexpression may offer a survival advantage against some cell death pathways. MCU inhibitors may be a strategy to increase the effectiveness of therapies that act through the induction of caspase-independent cell death pathways in estrogen receptor negat ive and basal-like breast cancers.
Introductio n
Mitochon dria regulate numerous cellular processes and are vital for both sustaining cell survival and the initiation of cell death [1, 2] . The uptake of Ca 2+ by mitochondria can buffer increases in cytosolic free Ca 2+ ([Ca 2+ ] CYT ) and stimulate specific mitochondr ial functions such as ATP synthesis [1, 2] . Mitochon drial Ca 2+ levels may also influence sensitivity to cell death activators [3, 4] . In malignant transformat ion, remodeling of Ca 2+ homeostas is and reprogramm ing of mitochondr ial functions could confer cancer cells with a survival advantage and an ability to evade cell death [5, 6] . Calcium transporters including the voltage-dep endent anion-selec tive channel (VDAC) and the mitochondrial Ca 2+ uniporter (MCU) [1] participate in mitochondr ial Ca 2+ uptake and have been proposed as potential regulator s of cell death [7, 8] .
Since the molecular identification of MCU [9, 10] , several studies have investigated the significance of mitochondr ial Ca 2+ uptake on specific cellular processes through the modulation of MCU expression levels. In cardiomyocy tes MCU silencing amplifies bulk [Ca 2+ ]-CYT and is associated with increased contractile responses [11] . In breast cancer cells sustained increases of bulk [Ca 2+ ] CYT are associated with the promotion of cell death responses [12] . However, the potential for MCU to modulate cell death and other events in breast cancer cells has not been investigated .
MCU has been studied in other cancer types. One recent study identified MCU down-regulati on as a characteri stic feature of some human colon and prostate cancer cells [13] . Down-regulati on of MCU in colon and prostate-derive d cancers promotes increased prolifera tion and bestows resistance to cell death stimuli through diminished mitochondrial Ca 2+ levels [13] . No studies have yet assessed MCU in the context of breast cancer.
In this study we assessed MCU expression in clinical breast cancers and evaluated the functional significance of MCU silencing on prolifera tion, cell death pathways and on bulk [Ca 2+ ] CYT in MDA-MB-231 breast cancer cells. Our results suggest that MCU inhibition may sensitize some breast cancers to some inducers of cell death.
Materials and methods

Analysis of MCU levels in human breast cancer cases
Gene expression data for 180 human breast cancer cases [14] were obtained from NCBI-GEO (Accession GSE3165) and imported into Partek Genomics Suite (version 6.6). MCU (annotated on these microarrays as C10orf42) expression was analyzed in samples grouped by both estrogen receptors status and PAM50 molecular subtype [15] .
Cell culture
Human MDA-MB-231 breast cancer cells (American Type Culture Collection) were grown in high glucose DMEM (Sigma Aldrich) supplemented with 10% FBS and 4 mM L-glutamine (Invitrogen) at 37°C/5% CO 2 in a humidified air incubator.
Silencing of MCU expression
MDA-MB-231 cells were transfected as previousl y described [12] with ON-TARGET plus ™ SMARTpool siRNAs (Dharmacon), consisting of four pooled siRNA sequence s rationally designed to minimize off-target effects [16, 17] . The specific siRNAs used in this study were MCU siRNA (siMCU, L-015519-0 2) and the non-targeting control siRNA (siNT, D-001810 -10). For all experime nts MCU mRNA silencing (>70%) was confirmed at 48 h post-siRN A.
Quantitative real time RT-PCR
Quantitative real time RT-PCR was performed as described previously [12] . Briefly, at 48 or 120 h post siRNA-transfecti on total RNA was isolated (RNeasy Plus mini kit; Qiagen), and then reverse transcribed (Omniscript RT kit; Qiagen). The cDNA of interest were amplified using the TaqMan Fast Universal PCR Master Mix (Applied Biosystems) and TaqMan Gene Expression assays (MCU, Hs00293548_m 1; 18 S rRNA, 4319413E; Applied Biosystems) under universal cycling conditions with a StepOnePlus real time PCR system (Applied Biosystems). MCU mRNA levels were quantified by the comparative Ct method as described [18] normalized to 18 S rRNA and presented relative to the siNT control.
Cell enumerati on and S-phase analysis
MDA-MB-23 1 cells were transfected with siRNA for 120 h and then cell enumeration and S-phase analysis were performed as previousl y described [19] . Briefly, cells with newly synthesized DNA were stained, according to the manufacturer's instructions using the Click-iT Ò EdU cell proliferation assay (Alexa Fluor 555; Invitrogen). DAPI-stained cell nuclei (400 nM; 90 min) and EdUpositive cells were imaged with a 10Âobjective using an ImageXpress Micro automated epifluorescence microscope (Molecular Devices Corporation ) [20] . Cell number and percentage of EdU positive cells were calculated using the multi-wavelen gth cell scoring applicati on module (MetaXpress v3.1.0.83; Molecular Devices).
Assessment of cell viability
At 72 h post siRNA-transfecti on MDA-MB -231 cells were treated with the cell death activators ABT-263 (Selleckchem), ionomycin (Enzo Life Sciences), or with dimethyl sulfoxide (up to 0.33%) and incubate d for an additional 48 h. Cell viability was then assessed in non-fixed cells as previously reported by evaluating Hoechst 33342 (10 lg/mL; Invitrogen) and propidium iodide (1 lg/mL; Invitrogen) staining [12] . Imaging was performed using an Imag-eXpress Micro automated epifluorescence microscope (Molecular Devices Corporation). Criteria for viable and propidium iodide positive cells (PI+) were defined as previousl y described [12] .
Cytosolic free Ca 2+ measuremen ts
At 72 h post siRNA-trans fection MDA-MB-23 1 breast cancer cells were loaded with either a high Ca 2+ affinity (Fluo-4AM (4 lM; Molecular Probes)) or a low Ca 2+ affinity (Fluo-4FF (4 lM; Molecular Probes)) Ca 2+ indicator according to published methods [12] . [Ca 2+ ] CYT was then monitored using a fluorescence imaging plate reader [21] (Molecular Devices Corporation ) as previously described [12] . To assess relative [Ca 2+ ] CYT fluorescence was normalized to base-line values.
Statistical analysis
Statistical tests were performed as described in the figure legends using GraphPad Prism version 5.04 for Windows . 
Results
MCU mRNA levels in clinical breast cancer samples
Assessment of MCU mRNA levels in a cohort of 180 breast cancer cases [14] showed a significantly (P < 0.05; Fig. 1A ) higher level of MCU in estrogen receptor (ER)-negative breast cancers. When breast cancers were stratified by molecular subtype the highest levels of MCU were seen in basal-like breast cancers (P < 0.05; basal-like versus luminal A and B subtypes; Fig. 1B ), while other subtypes expressed intermediated MCU levels ( Fig. 1B) . ER-negative and basal-like breast cancers are associate d with a particular ly poor prognosis [22, 23] .
Effects of MCU silencing on proliferation and cell viability in MDA-MB-231 breast cancer cells
To assess the possible role of MCU overexpression in breast cancer, we used specific siRNAs to silence MCU expression in basallike MDA-MB -231 breast cancer cells [24] . Compared to the siNT control, cells transfected with siMCU showed a significant (P < 0.05) decrease in MCU mRNA levels at 48 h ( Fig. 2A ) and 120 h (Fig. 2B ) post-siRNA. Using this model we assessed the effects of MCU knockdown on proliferation and cell viability.
Effects of MCU silencing on cell proliferation were evaluated by cell enumeration and S-phase analysis (EdU staining). MCU silencing did not significantly alter cell number (Fig. 2C ), or the percentage of cells in S-phase (EdU positive; Fig. 2D ) compared to the siNT control. Cell viability was also quantified; MCU silencing had no significant effect on the percentage of viable cells compared to the siNT control ( Fig. 2E-G) . 
MCU silencing sensitizes MDA-MB -231 breast cancer cells to ionomycin-m ediated cell death
To analyze whether MCU silencing regulates breast cancer cell responses to death activators , siRNA-trans fected MDA-MB-23 1 cells were treated with the Ca 2+ ionophore ionomycin to initiate caspase-ind ependent cell death [12] . Compared to the siNT control MCU silencing potentiated sub-maxim al ionomyc in (3 lM)-mediated cell death, with a significant (P < 0.05) reduction in cell viability and a marked (P < 0.05) increase in the proportio n of propidium iodide positive cells (Fig. 3A) . Silencing of MCU did not alter cell viability at a higher ionomycin concentration (10 lM) compared to the siNT control (Fig. 3B) . These data suggest MCU silencing sensitizes MDA-MB-231 cells to caspase-i ndependent cell death initiated with ionomycin.
MCU silencing does not modulate ABT-263-med iated MDA-MB-231 breast cancer cell death
The Bcl-2 inhibitor ABT-263 was used to address the consequence of MCU silencing on caspase-dep endent cell death in the MDA-MB-23 1 breast cancer cell line [12] . Compared with the siNT control, MCU silencing exerted no effect on cell death initiated at either the submaximal (3 lM; Fig. 3C ) or high (10 lM; Fig. 3D) ABT-263 concentr ations. This suggests that MCU knockdown does not sensitize MDA-MB-23 1 cells to caspase-dep endent cell death initiated by ABT-263.
Effects of MCU silencing on increases in bulk [Ca 2+ ] CYT
To assess whether MCU silencing modified the nature of bulk [Ca 2+ ] CYT increases, we challenged siRNA-transfected MDA-MB-231 breast cancer cells with different initiators of [Ca 2+ ] CYT in-creases. Moderate increases in bulk [Ca 2+ ] CYT were induced with the sarco-en doplasmic reticulum Ca 2+ -ATPase (SERCA) inhibitor cyclopiazon ic acid (CPA; 10 lM) or the protease activated receptor activator trypsin (0.1 lM) under Ca 2+ -free conditions. Compare d with the siNT control, silencing of MCU did not alter either CPA (Fig. 4A) or trypsin (Fig. 4C ) Ca 2+ responses, with no significant difference detected for area under the curve (Fig. 4B and D) or other Ca 2+ transient parameters such as peak [Ca 2+ ] CYT and half peak decay time (data not shown).
A role for MCU in shaping Ca 2+ signals of higher magnitude was evaluated in the presence of extracellular Ca 2+ (2 mM) using the Ca 2+ ionophor e ionomycin. Assessment of [Ca 2+ ] CYT with the low affinity Ca 2+ indicator Fluo-4FF, showed that MCU silencing compare d to the siNT control had no major effects on bulk [Ca 2+ ] CYT increases, at either submaximal (3 lM; Fig. 4E and F) or high (10 lM; Fig. 4G and H) ionomycin concentratio ns. Collectively, these findings demonstrate that MCU does not have a major role in the regulatio n of bulk [Ca 2+ ] CYT in MDA-MB-23 1 breast cancer cells.
Discussion
A previous study identified MCU downregulati on in prostate and colon-de rived cancers [13] , here we present data showing that MCU is upregulated in some clinical breast cancer subtypes. MCU was most highly expressed in ER-negative and basal-like breast cancers both of which are associated with a poor prognosis [22, 23] . To understand the implication of MCU overexpres sion in breast cancer, we assessed the functional consequences of MCU silencing on prolifera tion, cell death and bulk [Ca 2+ ] CYT in the basal-like MDA-MB -231 breast cancer cell line.
Our silencing studies in MDA-MB -231 cells showed MCU knockdow n had no effect on proliferation or cell viability. However, assessment of MCU knockdown on cell death initiated by ABT-263 and ionomycin defined a distinct role for MCU in the regulation of caspase-ind ependent and -dependent cell death pathways, respectively . MCU silencing did not affect ABT-263mediated cell death, but acted as a sensitizer of cell death initiated with ionomyc in. MCU silencing attenuates mitochondrial Ca 2+ uptake [9, 10] and reduced mitochondr ial Ca 2+ levels act to suppress cell death in a variety of malignant cell lines, including those derived from the cervix [4] central nervous system [25] , head and neck [26] and lymph [27] tissues. We therefore hypothesized that MCU knockdown in MDA-MB-231 breast cancer cells would also protect from death insults. However, MCU knockdown did not protect against ABT-263-in duced cell death, and potentiated ionomycin-init iated cell death. Alterations in bulk [Ca 2+ ] CYT signals were examined as a potential mechanism of MCU silencing-mediate d promotion of ionomycin-initiated cell death. In cardiomyocytes MCU silencing amplifies cytosolic Ca 2+ signals [11] and we have recently shown sustained increases of bulk [Ca 2+ ] CYT are associated with the promotion of ionomycin-m ediated MDA-MB -231 cell death [12] . However, our assessment of bulk [Ca 2+ ] CYT showed no major changes upon MCU knockdown on Ca 2+ signals stimulated with CPA, trypsin or ionomycin. These data suggest that MCU does not significantly contribute in buffering global cytosolic free Ca 2+ ; therefore increases in bulk [Ca 2+ ] CYT are unlikely to explain the promotion of ionomycin-i nitiated cell death upon MCU silencing.
The ability of MCU silencing to sensitize MDA-MB-231 cells to ionomycin-m ediated cell death could be due to diminished mitochondrial Ca 2+ uptake and alterations in the autophagy survival pathway, as the specific MCU inhibitor Ru360 regulates autophagy in HEK293 and DT40 cells [28] . Another mechanis m may involve alterations in localized Ca 2+ signals within specializ ed signaling domains at the endoplasmic reticulum-m itochondria l interface, known as mitochondrial-associated-mem branes (MAMs) [29] . A recent study investiga ted reduced mitochondr ial Ca 2+ uptake through knockdown of the MAM-enrich ed calcium transporter, VDAC1 [30] . VDAC1 silencing potentiates the response of humanderived HeLa cervical cancer cells to death activators without affecting bulk [Ca 2+ ] CYT , this sensitization was not depende nt on diminished mitochondr ial Ca 2+ levels [30] . Localized Ca 2+ signals possibly within MAM domains may represent another regulatory site for Ca 2+ -dependent death signals in breast cancer cells and along with MCU-me diated regulation of autophagy requires further investigation.
In this report, we have identified MCU overexpression in some clinical breast cancers, in particular those subtypes associated with a poor prognosis (estrogen receptor negative and basal-like). MCU silencing in the basal-like MDA-MB-231 breast cancer cell line promoted ionomycin-init iated but not ABT-263-mediated cell death. MCU inhibitors may therefore represent novel therapies for some breast cancers by potentiating some caspase-i ndependent cell death mechanis ms.
